First-year costs of treating prostate cancer: Estimates from SEER-Medicare data

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 4, 2009, Pages 355-360

  Roehrborn, C G ^a   Albertsen, P ^b   Stokes, M E ^c   Black, L ^d   Benedict, A ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNITED BIOSOURCE CORPORATION   (Canada)

^d GLAXOSMITHKLINE   (United States)

^e United BioSource Corporation   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

GOSERELIN; LEUPRORELIN; TRIPTORELIN;

AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY ANALYSIS;

AGED; AGED, 80 AND OVER; DRUG THERAPY; HEALTH CARE COSTS; HUMANS; MALE; MEDICARE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 70749111420     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.21     Document Type: Article

References (19)

1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215.
2. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman Jr CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prev Res 2008; 1: 174.
3. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: Implications for prostate cancer detection and chemoprevention. Cancer Prev Res 2008; 1: 167.
4. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial. Cancer Prev Res 2008; 1: 182.
5. Logothetis CJ, Schellhammer PF. High-grade prostate cancer and the Prostate Cancer Prevention Trial. Cancer Prev Res 2008; 1: 151.
6. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. J Urol 2004; 172: 1314.
7. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87: 417.
8. Penberthy L, Retchin SM, McDonald MK, McClish DK, Desch CE, Riley GF et al. Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer. Health Care Manag Sci 1999; 2: 149.
9. Penson DF, Schonfeld WH, Flanders SC, Henke CJ, Warolin KL, Carroll PR et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results fromthe CAPSURE database. Urology 2001; 57: 499.
10. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008; 100: 888.
11. Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer. Med Care 2007; 45: 154.
12. Brandeis J, Pashos CL, Henning JM, Litwin MS. A nationwide charge comparison of the principal treatments for early stage prostate cancer. Cancer 2000; 89: 1792.
13. National Cancer Institute. Surveillance, Epidemiology, and End Results: About SEER. National Cancer Institute: Bethesda, MD, 2008. Available at: http://seer.cancer.gov/about. Accessed September 2008.
14. American Joint Committee on Cancer. Past Editions of the AJCC Cancer Staging Manual. American Joint Committee on Cancer: Chicago, 2008. Available at: http://www.cancerstaging.org/products/pasteditions.html. Accessed March 2008.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613.
16. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman and Hall: New York, 1993.
17. Litwin MS, Pasta DJ, Stoddard ML, Henning JM, Caroll PR. Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993. J Urol 1998; 160: 445.
18. Iezzoni LI. Assessing quality using administrative data. Ann Intern Med 1997; 127: 666.
19. Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 2008; 26: 2278.